Medications and Drugs
Brand Names: In-111 Zevalin, Y-90 Zevalin
Generic Name: ibritumomab (Pronunciation: ib ri TYOO mo mab)
What is ibritumomab (In-111 Zevalin, Y-90 Zevalin)?
Ibritumomab is used in combination with other medicines to treat non-Hodgkin's lymphoma.
Ibritumomab may also be used for purposes than those listed in this medication guide.
What are the possible side effects of ibritumomab (In-111 Zevalin, Y-90 Zevalin)?
Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
Less serious side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the most important information I should know about ibritumomab (In-111 Zevalin, Y-90 Zevalin)?
Do not receive this medication if you are pregnant. It could cause harm to the unborn baby. Use an effective form of birth control, and tell your doctor if you become pregnant during treatment.
Ibritumomab can lower blood cells that help your body fight infections. Your blood may need to be tested often. Avoid being near people who are sick or have infections. Avoid activities that may increase your risk of bleeding injury. Tell your doctor at once if you develop signs of infection.
Do not receive a "live" vaccine while you are being treated with ibritumomab, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you.
Some people receiving ibritumomab have developed "secondary" bone marrow or blood cell cancers such as leukemia. Talk with your doctor about your individual risk while receiving this medication.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?